Professor Jasmohan Bajaj talks about the overuse and misuse of antibiotics and how this will cause an international pandemic, if the "reset-button" to deescalate the use of antibiotics is not pressed soon.
Professor Subrata Ghosh summarises the key findings of the ICONIC-study, which is the largest ongoing observational study on the burden of adult ulcerative colitis in patients under routine care. It comprises 1.816 enrolled patients in 33 countries throughout the globe.
Crohn’s disease (CD) is a progressive disorder and the achievement of mucosal healing lowers the risk of necessary surgery, according to Julián Panés (Spain).
As early as week 2, patient-reported symptomatic improvements were achieved among UC patients treated with vedolizumab – including a combined reduction in defecation frequency and rectal blood loss. These findings underline the fast action of vedolizumab in treating UC, particularly when it is used as a first-line biological therapy.
During the word of welcome given at the satellite symposium 'Rapid Action and Lasting Remission - Focus on Disease Progression in Ulcerative Colitis', William Sandborn came directly to the point: the sufficient treatment of UC is essential. In 50% of the patients suffering from the UC, the disease takes an adverse course.
A bridging strategy in which a calcineurin inhibitor and vedolizumab are combined seems to be effective in patients with active steroid-refractory ulcerative colitis. Such a strategy could be considered for patients with acute, severe UC and nonsevere UC that are resistant to conventional therapy, including anti-tumour necrosis factor (anti-TNF).
Professor Pierre Michetti summarizes new approaches in the treatment of ulcerative colitis.
In our interview, Professor Janindra Warusavitarne talks about minimally invasive surgical intervention for patients with severe ulcerative colitis.
Professor Chris Probert talks about the current state of research and presents results of a recent study on clinical efficacy and patient safety of Golimumanb for induction and maintenance in patients with moderate to severe colitis ulcerosa.
Dr. Peter Bossuyt summarizes his scientific talk about results of the Real Life - BE SMART study. He primarily speaks about an early mucosal healing in connection with the TNF-α inhibitor Golimumab.
From biologicals to microbiome: Dr. Johan Burisch informs about the most exciting developments in research and treatment of chronic inflammatory bowel disease (IBD).